EDAP
EDAP TMS S.A.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Thu, Nov. 17, 7:16 AM
    • EDAP TMS SA (NASDAQ:EDAP) booked €8.0M in revenues in Q3 led by a 108% increase in HIFU sales. Net income was €1.3M (+127%).
    • Management will host a conference call today at 8:30 am ET to discuss the results.
    | Thu, Nov. 17, 7:16 AM
  • Thu, Nov. 17, 7:12 AM
    • EDAP TMS S.A. (NASDAQ:EDAP): Q3 EPS of €0.04
    • Revenue of $8.9M (+25.4% Y/Y)
    • Press Release
    | Thu, Nov. 17, 7:12 AM
  • Thu, Aug. 25, 9:16 AM
    | Thu, Aug. 25, 9:16 AM | 2 Comments
  • Thu, Aug. 25, 8:02 AM
    • EDAP TMS S.A. (EDAP) Q2 results: Revenues: $9.2M (+5.7%); Operating Loss: ($0.4M); Net Income: $2.8M; EPS: $0.09; Quick Assets: $24.2M (+45.8%).
    • Shares up 29% premarket on increased volume.
    • No guidance given.
    | Thu, Aug. 25, 8:02 AM | 3 Comments
  • Thu, Aug. 25, 7:09 AM
    • EDAP TMS S.A. (NASDAQ:EDAP): Q2 EPS of $0.09 beats by $0.12.
    • Revenue of $9.2M (+17.8% Y/Y) beats by $0.59M.
    • Press Release
    | Thu, Aug. 25, 7:09 AM
  • Fri, Jun. 3, 7:37 AM
    • Bayer (OTCPK:BAYRY) and Espoo, Finland-based Orion expand their 2014 agreement to jointly develop BAY-1841788 (ODM-201) in prostate cancer, currently in Phase 3 development (ARAMIS study) for the treatment of high-risk non-metastatic castration-resistant prostate cancer.
    • The new indication will be for the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer, in combination with docetaxel, in men who are starting first-line hormone therapy.
    • A Phase 3 study, called ARASENS, will begin enrolling patients in late Q4. The double-blind, placebo-controlled trial will randomize ~1,300 subjects 1:1 to receive either BAY-1841788 (ODM-201) or placebo in combination with an androgen deprivation therapy of the investigator's choice started no more than 12 weeks before randomization. The primary endpoint is overall survival.
    • BAY-1841788 is an oral androgen receptor antagonist.
    • Prostate cancer-related tickers: (NASDAQ:MDVN)(OTCPK:ALPMY)(NYSE:VRX)(NASDAQ:TTHI)(NASDAQ:EDAP)(NASDAQ:TKAI)(NYSE:JNJ)(NASDAQ:TSRO)(NYSE:AZN)(NASDAQ:EGRX)(NASDAQ:OGXI)
    | Fri, Jun. 3, 7:37 AM
  • Wed, May 18, 8:11 AM
    • EDAP TMS S.A. (EDAP) Q1 results: Revenues: $9.6M (+39.1%); R&D Expense: $0.9M (+4.7%); SG&A: $3.1M (+14.8%); Operating Income: $0.8M (+214.3%); Net Income: $1.5M (+155.6%); EPS: $0.06 (+154.5%); Quick Assets: $16.6M (+5.1%).
    • No guidance given.
    • Shares are up 14% premarket on light volume.
    | Wed, May 18, 8:11 AM | 1 Comment
  • Wed, May 18, 7:04 AM
    • EDAP TMS S.A. (NASDAQ:EDAP): Q1 EPS of $0.06 beats by $0.08.
    • Revenue of $9.6M (+39.1% Y/Y) beats by $2.8M.
    | Wed, May 18, 7:04 AM
  • Fri, Apr. 15, 9:50 AM
    • EDAP TMS SA (EDAP -0.3%) has closed its previously announced $11.5M direct placement of 3,283,284 ordinary shares in the form of American Depositary Shares (ADSs) at $3.50 per share plus an associated warrant for one ordinary share (as an ADS). Net proceeds will fund the acceleration of HIFU commercial activities in the U.S., including hiring additional sales, marketing and support personnel and a ramp-up of marketing programs.
    • The company's Ablatherm Integrated Imaging HIFU (high-intensity focused ultrasound) system was granted 510(k) clearance in November 2015 for the treatment of prostate cancer via ablating (removing tissue by vaporizing) the tissue.
    | Fri, Apr. 15, 9:50 AM
  • Thu, Apr. 7, 9:35 AM
    • Lyon, France-based EDAP TMS SA (EDAP -7.7%) inks agreements with institutional investors for the direct placement of 3,283,284 ordinary shares at $3.50 per share, generating gross proceeds of ~$11.5M. Investors will also receive one two-year warrant to purchase one ordinary share at $4.50 for each share acquired. The warrants are exercisable in six months. Closing date is April 14.
    • Shares are down 11% on light volume.
    | Thu, Apr. 7, 9:35 AM
  • Mon, Apr. 4, 9:13 AM
    | Mon, Apr. 4, 9:13 AM
  • Mon, Apr. 4, 7:22 AM
    • EDAP TMS S.A. (EDAP) Q4 results (€): Revenues: 11.8M (+81.5%); R&D Expense: 0.6M (-5.0%); SG&A: 3.1M (+6.9%); Operating Income: 1.6M (+260.0%); Net Income: 5.1M (+296.2%); EPS: 0.18 (+263.6%).
    • FY2015 results: Revenues: 32.3M (+20.5%); R&D Expense: 2.7M (-6.9%); SG&A: 10.6M (+6.0%); Operating Income: 0.5M (+129.4%); Net Loss: (1.7M) (-240.0%); Loss Per Share: (0.07) (-250.0%); Quick Assets: 14.6M (+31.5%).
    • No guidance given.
    | Mon, Apr. 4, 7:22 AM
  • Mon, Apr. 4, 7:04 AM
    • EDAP TMS S.A. (NASDAQ:EDAP): Q4 EPS of €0.18
    • Revenue of €11.8M (+81.5% Y/Y)
    | Mon, Apr. 4, 7:04 AM
  • Nov. 19, 2015, 8:16 AM
    • EDAP TMS S.A. (EDAP +0.7%) Q3 results (€): Revenues: 6.4M (-7.2%); R&D Expense: 0.6M (-14.3%); SG&A: 2.2M (-8.3%); Operating Loss: (0.3M) (-200.0%); Net Loss: (4.8M) (-172.7%); Loss Per Share: (0.19) (-173.1%); Quick Assets: 11.1M (-4.3%).
    • No guidance given.
    | Nov. 19, 2015, 8:16 AM
  • Nov. 18, 2015, 5:59 PM
    • EDAP TMS S.A. (NASDAQ:EDAP): Q3 EPS of -€0.19 vs. €0.26 in 3Q14
    • Revenue of €6.4M ( -7.2% Y/Y )
    | Nov. 18, 2015, 5:59 PM
  • Nov. 9, 2015, 9:14 AM
    | Nov. 9, 2015, 9:14 AM